Rhinovirus
23
2
2
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
4.3%
1 terminated out of 23 trials
92.9%
+6.4% vs benchmark
13%
3 trials in Phase 3/4
54%
7 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (23)
A Study of APL-10456-Vaccine
The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics
Impact of the Covid-19 on RSV
Impact of the Covid-19 on RSV Epidemic in the Metropolis of Lyon
Impact of Covid-19 on Rhinovirus Epidemic
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers.
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma
'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'
The Respiratory Protection Effectiveness Clinical Trial
A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
Collection and Testing of Respiratory Samples
Specific Respiratory Infections as Triggers of Acute Medical Events